🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Lymphatic Diseases

Registry of the German CLL Study Group NCT02863692n/a1 site📍 Dresden German CLL Study Group ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants NCT06787144Phase 14 sites📍 Akita📍 Sapporo📍 Suita-shi Enliven Therapeutics · Tests: ELVN-001 A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites📍 Gilbert📍 Scottsdale📍 Scottsdale Lyell Immunopharma, Inc. · Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency NCT07347249Phase 21 site📍 London Hemab ApS · Tests: Sutacimig, Sutacimig Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents NCT05442216Phase 27 sites📍 Miami📍 Orlando📍 Buffalo Joshua Zeidner · Tests: Tagraxofusp, Azacitidine, Venetoclax Sickle-cell Disease Registry of the GPOH NCT03327428n/a1 site📍 Heidelberg University Hospital Heidelberg Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients NCT07313592n/a1 site📍 St Louis Washington University School of Medicine Weekly Sirolimus Therapy NCT04861064Phase 21 site📍 Charleston Medical University of South Carolina · Tests: Sirolimus Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant NCT03921047n/a1 site📍 Los Angeles University of Southern California · Tests: Biospecimen Collection, Laboratory Biomarker Analysis A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184Phase 144 sites📍 Phoenix📍 La Jolla📍 Los Angeles Kura Oncology, Inc. · Tests: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma NCT07284758Phase 260 sites📍 Huntsville📍 Phoenix📍 Scottsdale C4 Therapeutics, Inc. · Tests: Cemsidomide, Dexamethasone An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A NCT07088458n/a12 sites📍 Loma Linda📍 New Brunswick📍 Many Locations Bayer · Tests: Damoctocog alfa pegol (Jivi, Bay94-9027) Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs NCT06111638Phase 2, Phase 310 sites📍 Beijing📍 Guangzhou📍 Guiyang Shanghai Xinzhi BioMed Co., Ltd. · Tests: Single dose intravenous injection of BBM-H803 Effect of Fish Oil on Hyperlipidemia and Toxicities in Children and Young Adults With Acute Lymphoblastic Leukemia NCT04209244NA4 sites📍 Aalborg📍 Aarhus📍 Copenhagen Copenhagen University Hospital, Rigshospitalet · Tests: Eskimo-3 Pure Fish Oil, Rapeseed Oil CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma NCT05948033Phase 1, Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: CD70-targeting CAR-T cells Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance NCT06483100Phase 21 site📍 St Louis Washington University School of Medicine · Tests: Elrantamab, clonoSEQ Peking University Birth Cohort in Weifang (PKUBC-WF) NCT06234332n/a1 site📍 Beijing Peking University · Tests: No Interventions TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies NCT06484816Phase 11 site📍 Hangzhou Shenzhen TargetRx Co., Ltd. · Tests: TGRX-1942 Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma NCT05896228Phase 21 site📍 Miami Benjamin T Diamond, MD · Tests: Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma NCT05645107Phase 362 sites📍 Bullhead City📍 Huntington Park📍 St. Petersburg Grifols Therapeutics LLC · Tests: Xembify, Placebo Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia NCT06184009Phase 29 sites📍 Seoul📍 Seoul📍 Incheon Jae Wook Lee · Tests: ALL, High risk Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma NCT06160843Phase 21 site📍 Singapore National Cancer Centre, Singapore · Tests: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET NCT05093335EARLY Phase 11 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: [68Ga]-Pentixafor PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06530550Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: PI3K inhibitor Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain NCT07624838n/a37 sites📍 A Coruña📍 Palma de Mallorca📍 Palma de Mallorca Grupo Español de Linfomas y Transplante Autólogo de Médula … · Tests: Brentuximab Vedotin Plus CHP BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008Phase 21 site📍 Beijing Peking University People's Hospital · Tests: BCMA-CD19 CAR-T therapy A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites📍 Duarte📍 La Jolla📍 Ann Arbor Incyte Corporation · Tests: INCA036873 Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049Phase 1, Phase 23 sites📍 Minneapolis📍 Columbus📍 Richmond Yazeed Sawalha · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia NCT06429449Phase 11 site📍 Aurora University of Colorado, Denver · Tests: Venetoclax, Azacitidine, Mitoxantrone Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. NCT04915248Phase 218 sites📍 Ancona📍 Aviano📍 Florence Fondazione Italiana Linfomi - ETS · Tests: Daratumumab, Bortezomib, Dexamethasone
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy